TNFRSF17 and plasma cell myeloma: On one side, this leads to reduced ligand density on myeloma cells, and on the other side, sufficient sBCMA can accumulate in the bone marrow and inhibit BCMA antibody binding or CAR T-cell recognition of myeloma cells.